Amylyx Pharmaceuticals (AMLX) Equity Average: 2022-2025
Historic Equity Average for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $249.9 million.
- Amylyx Pharmaceuticals' Equity Average rose 9.26% to $249.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.9 million, marking a year-over-year increase of 9.26%. This contributed to the annual value of $299.1 million for FY2024, which is 22.72% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Equity Average stood at $249.9 million, which was up 35.36% from $184.6 million recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Equity Average peaked at $425.9 million during Q4 2023, and registered a low of $44.9 million during Q1 2022.
- Moreover, its 3-year median value for Equity Average was $292.9 million (2024), whereas its average is $294.8 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Equity Average skyrocketed by 672.19% in 2023 and then slumped by 57.62% in 2024.
- Quarterly analysis of 4 years shows Amylyx Pharmaceuticals' Equity Average stood at $242.3 million in 2022, then skyrocketed by 75.77% to $425.9 million in 2023, then crashed by 57.62% to $180.5 million in 2024, then increased by 9.26% to $249.9 million in 2025.
- Its Equity Average was $249.9 million in Q3 2025, compared to $184.6 million in Q2 2025 and $183.1 million in Q1 2025.